ivicentamab (GEN-3009) / Genmab  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ivicentamab (GEN-3009) / Genmab
NCT04358458 / 2019-002752-16: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Terminated
1/2
46
Europe, US
GEN3009, DuoHexaBody®-CD37, Epcoritamab, DuoBody®-CD3xCD20, GEN3013, EPKINLY™
Genmab, AbbVie
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma
11/22
07/23

Download Options